Hims & her products were shown.
He and hers
Shares Hims & Her Health FDA fell more than 23% on Friday Announce The shortage of Semaglutide injection products has been resolved.
semaglutide is an active ingredient Novo NordiskOzempic’s blockbuster weight loss medication and diabetes treatment. These drugs are part of a class of drugs called GLP-1, and the need for treatment has exploded in recent years. As a result, digital health companies like Hims & her are prescribing more complex Semaglutides to replace patients with volatile supply and insurance disorders.
Complex drugs are custom alternatives to branded drugs designed to meet the needs of specific patients, and they can be produced when used in branded treatments. shortage. FDA No review Safety and efficacy of composite products.
Hims & hers begin to offer patients more complex semaglutides in Mayand owns a compound pharmacy that produces drugs.
Complex drugs are often much cheaper than their brand peers. Hims & Hers sells compound Semaglutide for less than $200, while Ozempic and Wegovy from Novo Nordisk both cost about $1,000 without insurance.
Depending on the type of facility, it will begin taking infringement actions against compounders over the next 60 to 90 days to avoid “avoiding unnecessary damage to patient treatment”, the FDA said Friday.
Hims & Hers CEO Andrew Dudum, “Now that the FDA has identified the drug shortage at Semaglutide, we will continue to provide personalized treatments permitted by law to meet the needs of patients.” Posted on X Friday. “We are also closely monitoring potential future shortages, as Novo Nordisk said two weeks ago, it will continue to have ‘capacity limits’ and “anticipated ongoing periodic supply restrictions and related drug shortage notifications.”
The company’s weight loss products have been hit hard by investors. The company’s stock price climbed more than 200% last year, despite Friday’s move, stock has risen more than 100% this year.
The company even before adding GLP-1 to its portfolio 2023 fourth quarter revenue Calls it expects its weight loss program to bring in more than $100 million in revenue by the end of 2025.
Despite the turbulent regulatory landscape, Hims and Hers showed no sign of slowing down.
Friday, the company Announce It has acquired a U.S.-based peptide facility that will “further vertically enable the company to deliver long-term capabilities of personalized medicines.” Hims & hers will explore advances in metabolic optimization, recovery of science, biological resistance, cognitive performance and prevent health through acquisitions The company says.
This move came a few days after he and she bought it too Trybe Labsa home lab testing facility in New Jersey. Trybe Labs Will allow him and hers Performance at home with blood And more comprehensive preprocessing tests.
Hims & hers did not disclose any terms of a deal.
